📊 NGNE Key Takeaways
Is Neurogene Inc. (NGNE) a Good Investment?
Neurogene is a pre-revenue biotech company with adequate financial resources but zero revenue and significant operating losses of $33.3M. While the strong balance sheet ($237.8M equity, $124.2M cash) provides 4+ years of runway, the lack of commercial traction and persistent operating losses indicate the company remains entirely dependent on unreported clinical and regulatory outcomes.
Neurogene is a pre-revenue developer with a strong balance sheet—ample cash, minimal liabilities, and no debt—providing a reasonable runway to progress programs. However, operating losses and cash burn remain substantial and net losses appear elevated year over year. Until there is clear evidence of clinical milestones translating into partnerships or initial revenue, fundamentals are neutral.
Neurogene Inc. Key Strengths (NGNE)
- Strong balance sheet with $237.8M stockholders' equity and no long-term debt
- Excellent liquidity position with $124.2M cash and 13.08x current ratio
- Low liability burden ($25.4M) providing financial flexibility for operations
- Robust liquidity and 16.56x current ratio
- No long-term debt and low liabilities
- Large equity base relative to assets/liabilities
NGNE Stock Risks: Neurogene Inc. Investment Risks
- Zero revenue indicates completely pre-revenue stage with no commercial validation
- Large operating losses ($33.3M) and negative operating cash flow ($26.1M) indicate ongoing cash burn
- Binary outcome risk - profitability and success entirely dependent on unreported clinical/regulatory milestones
- EPS deeply negative at -$1.39 with no clear path to profitability
- Zero revenue with continued large net losses
- High operating cash burn shortening runway
- Execution/clinical and financing risk leading to potential dilution
Key Metrics to Watch
- Revenue recognition and first commercial sales timeline
- Operating cash flow trends and cash runway extension
- Clinical trial progress and regulatory approval milestones
- Cash & equivalents
- Operating cash flow (burn rate)
Neurogene Inc. (NGNE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.08x current ratio provides a solid financial cushion.
NGNE Profit Margin, ROE & Profitability Analysis
NGNE vs Healthcare Sector: How Neurogene Inc. Compares
How Neurogene Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neurogene Inc. Stock Overvalued? NGNE Valuation Analysis 2026
Based on fundamental analysis, Neurogene Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neurogene Inc. Balance Sheet: NGNE Debt, Cash & Liquidity
NGNE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neurogene Inc.'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-4.28 indicates the company is currently unprofitable.
NGNE Revenue Growth, EPS Growth & YoY Performance
NGNE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$16.9M | $-0.99 |
| Q2 2025 | N/A | -$16.9M | $-1.05 |
| Q3 2024 | N/A | -$11.9M | $-1.19 |
| Q2 2024 | N/A | -$11.9M | $-1.09 |
| Q3 2019 | $25.0M | -$15.0M | N/A |
| Q2 2019 | $25.0M | -$1.0K | $-0.09 |
| Q3 2018 | $25.0M | -$11.8M | N/A |
| Q2 2018 | $25.0M | $2.9M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neurogene Inc. Dividends, Buybacks & Capital Allocation
NGNE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neurogene Inc. (CIK: 0001404644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NGNE
What is the AI rating for NGNE?
Neurogene Inc. (NGNE) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NGNE's key strengths?
Claude: Strong balance sheet with $237.8M stockholders' equity and no long-term debt. Excellent liquidity position with $124.2M cash and 13.08x current ratio. ChatGPT: Robust liquidity and 16.56x current ratio. No long-term debt and low liabilities.
What are the risks of investing in NGNE?
Claude: Zero revenue indicates completely pre-revenue stage with no commercial validation. Large operating losses ($33.3M) and negative operating cash flow ($26.1M) indicate ongoing cash burn. ChatGPT: Zero revenue with continued large net losses. High operating cash burn shortening runway.
What is NGNE's revenue and growth?
Neurogene Inc. reported revenue of $0.0.
Does NGNE pay dividends?
Neurogene Inc. does not currently pay dividends.
Where can I find NGNE SEC filings?
Official SEC filings for Neurogene Inc. (CIK: 0001404644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NGNE's EPS?
Neurogene Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NGNE's fundamental grade?
Based on our AI fundamental analysis in May 2026, Neurogene Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NGNE stock overvalued or undervalued?
Valuation metrics for NGNE: ROE of -13.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NGNE's AI grade for 2026?
Our dual AI analysis gives Neurogene Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NGNE's free cash flow?
Neurogene Inc.'s operating cash flow is $-26.1M, with capital expenditures of $281.0K.
How does NGNE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.0% (avg: 15%), current ratio 13.08 (avg: 2).